Research updates, September 29
A small clinical trial found Remdesivir was safe for people with Long COVID and that some exploratory results warrant a larger trial. The U.K. trial, which included 73 participants who took a five day course of the intravenous antiviral COVID-19 drug, was published in Oxford Open Immunology. The post Research updates, September 29 first appeared on The Sick Times .
The Sick Times recently launched a survey to gather more information on how they can better cater to their readers. The survey, which lasts about five minutes, will automatically save as you progress through it. Interested readers can access the survey here .
A small clinical trial conducted in the United Kingdom has found that Remdesivir is safe for individuals suffering from Long COVID, with some preliminary results suggesting a need for a larger study. The trial involved 73 participants who received a five-day course of the intravenous antiviral COVID-19 drug. The research was published in Oxford Open Immunology.
The study also included exploratory analyses, such as patient-reported outcomes and a six-minute walking test, which showed that Remdesivir helped alleviate fatigue and improve physical performance. However, the study did not include a placebo group. The study's author, Mark Faghy, cautioned that these findings should be interpreted with caution but indicated a strong case for further investigation.
According to a new study published in the American Journal of Industrial Medicine, one in ten healthcare workers in the United States reported ongoing Long COVID symptoms by 2024. The survey included 1,496 participants from 17 states who tested positive for COVID-19 between August 2022 and May 2024. All participants completed two surveys, one three months and one six months after their infections. More than 11% of participants reported at least one persistent symptom of Long COVID in both surveys.
A larger study conducted in the United Kingdom found that one in four healthcare workers reported Long COVID earlier in the pandemic. This earlier study was previously reported by The Sick Times.
PolyBio Research Foundation has recently announced $15 million in funding for its Long COVID Cure Initiative, which aims to speed up the development of treatments for Long COVID. The funding announcement was made at an event in Boston, attended by Massachusetts Governor Maura Healey and other funders, Steve and Judy Pagliuca. Governor Healey emphasized the importance of support for those living with Long COVID during her remarks at the event, stating, "To everyone living with Long COVID: we see you, we hear you, and we are committed to making sure you have the treatments and support you deserve."
In addition to its focus on Long COVID, PolyBio has also expanded its clinical research infrastructure to include chronic Lyme disease.
Written by urgent.news from The Sick Times's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
